• Search
  • Advanced Search

Others

  • HOME
  • ARTICLE CATEGORY
  • Others
Erratum
1981
Erratum to ‘Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction’ [Clin Mol Hepatol 2024;30:539-560]
Mehrangiz Dezhbord, Seong Ho Kim, Soree Park, Da Rae Lee, Nayeon Kim, Juhee Won, Ah Ram Lee, Dong-Sik Kim, Kyun-Hwan Kim
Clin Mol Hepatol. 2024;30(4):1060-1065.   Published online July 24, 2024
View: 1551   Download: 33  Web of Science: 1  Crossref: 1
Reply to Correspondence
Reply to correspondence on “Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction”
Cho-Rong Lee, Sung-Gyoo Park
Clin Mol Hepatol. 2024;30(4):1053-1054.   Published online July 17, 2024
View: 1826   Download: 48  Web of Science: 1  Crossref: 1
Reply to correspondence on “Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy”
Seren M. Gedallovich, Paul Y. Kwo
Clin Mol Hepatol. 2024;30(4):1050-1052.   Published online July 12, 2024
View: 1645   Download: 38
Reply to correspondence on “Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity: A longitudinal real-world study”
Jae Hyun Bae
Clin Mol Hepatol. 2024;30(4):1047-1049.   Published online August 19, 2024
View: 1575   Download: 58
Reply to correspondence on “Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients”
Beom Kyung Kim
Clin Mol Hepatol. 2024;30(4):1044-1046.   Published online July 29, 2024
View: 1360   Download: 28
Reply to correspondence on “Severity of microvascular invasion does matter in hepatocellular carcinoma prognosis”
Abdelrahman M Attia, Hasmik Adetyan, Ju Dong Yang
Clin Mol Hepatol. 2024;30(4):1042-1043.   Published online August 27, 2024
View: 1486   Download: 32  Web of Science: 1  Crossref: 3
Reply to correspondence on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis”
Tian-Yi Ren, Mohammed Eslam, Jian-Gao Fan
Clin Mol Hepatol. 2024;30(4):1039-1041.   Published online September 24, 2024
View: 1337   Download: 31
Reply to correspondence on “Protein-centric omics analysis reveals circulating complements linked to non-viral liver diseases as potential therapeutic targets”
Mohammad Saeid Rezaee-Zavareh, Naomy Kim, Ju Dong Yang
Clin Mol Hepatol. 2024;30(4):1037-1038.   Published online May 2, 2024
View: 1797   Download: 56
Reply to correspondence on “Comparison of four histological scoring systems for autoimmune hepatitis to improve diagnostic sensitivity”
Atsumasa Komori
Clin Mol Hepatol. 2024;30(4):1035-1036.   Published online April 11, 2024
View: 1778   Download: 45
Reply to correspondence on “Prognosis of biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: A sub-analysis of the CLIONE study”
Eileen Laurel Yoon, Dae Won Jun
Clin Mol Hepatol. 2024;30(4):1033-1034.   Published online May 20, 2024
View: 1530   Download: 31
Reply to correspondence on “Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide”
Pin-Nan Cheng, Ming-Lung Yu
Clin Mol Hepatol. 2024;30(4):1031-1032.   Published online April 11, 2024
View: 1941   Download: 63
Correspondence
Correspondence on editorial regarding “Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction”
Mehrangiz Dezhbord, Kyun-Hwan Kim
Clin Mol Hepatol. 2024;30(4):1028-1030.   Published online July 9, 2024
View: 1904   Download: 90  Crossref: 1
Correspondence to editorial on “Macrophage ATG16L1 expression suppresses metabolic dysfunction-associated steatohepatitis progression by promoting lipophagy”
Qi Wang, Qingfa Bu, Haoming Zhou, Ling Lu
Clin Mol Hepatol. 2024;30(4):1026-1027.   Published online July 8, 2024
View: 1422   Download: 52
Perspective of the risk and molecular mechanisms of hepatocellular carcinoma after HCV eradication in the post-DAA era: Correspondence to editorial on “Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication”
Chung-Feng Huang, Manar Hijaze Awad, Meital Gal-Tanamy, Ming-Lung Yu
Clin Mol Hepatol. 2024;30(4):1023-1025.   Published online July 1, 2024
View: 1986   Download: 52  Web of Science: 1  Crossref: 3
1962
The role of SPP1 in MASLD pathogenesis: Therapeutic insights into ursolic acid’s mechanisms of action: Correspondence to editorial on “Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 cells against metabolic dysfunction-associated steatotic liver disease”
Yiyuan Zheng, Zhekun Xiong, Lina Zhao, Chaoyuan Huang, Qiuhong Yong, Dan Fang, Fengbin Liu, Yong Li
Clin Mol Hepatol. 2024;30(4):1019-1022.   Published online July 8, 2024
View: 1946   Download: 62
Correspondence to editorial on “Conventional and machine learning-based risk scores for patients with early-stage hepatocellular carcinoma”
Chun-Ting Ho, Elise Chia-Hui Tan, Chien-Wei Su
Clin Mol Hepatol. 2024;30(4):1016-1018.   Published online May 20, 2024
View: 1719   Download: 41  Web of Science: 1  Crossref: 1
Correspondence to editorial on “Dynamic analysis of acute deterioration in chronic liver disease patients using modified quick sequential organ failure assessment”
Do Seon Song, Dong Joon Kim
Clin Mol Hepatol. 2024;30(4):1012-1015.   Published online June 18, 2024
View: 1596   Download: 22
Correspondence to editorial on “Multiomics profiling of buffy coat and plasma unveils etiology-specific signatures in hepatocellular carcinoma”
Su Bin Lim, Hyo Jung Cho
Clin Mol Hepatol. 2024;30(4):1009-1011.   Published online May 20, 2024
View: 1780   Download: 76  Crossref: 1
Correspondence to editorial on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study”
Young Eun Chon, Dong Yun Kim, Hong Jae Chon, Do Young Kim
Clin Mol Hepatol. 2024;30(4):1005-1008.   Published online May 30, 2024
View: 1854   Download: 67
Correspondence to editorial on “Liver sinusoidal endothelial cell: An important yet often overlooked player in the liver fibrosis”
Jiaorong Qu, Le Wang, Xiaojiaoyang Li
Clin Mol Hepatol. 2024;30(4):1002-1004.   Published online May 17, 2024
View: 1853   Download: 57
Correspondence to editorial on “Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity: A longitudinal real-world study”
Vy H. Nguyen, Mindie H. Nguyen
Clin Mol Hepatol. 2024;30(4):1000-1001.   Published online August 5, 2024
View: 1333   Download: 41
Correspondence to editorial on “Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study”
Chang Hun Lee, In Hee Kim, Sook-Hyang Jeong
Clin Mol Hepatol. 2024;30(4):997-999.   Published online July 29, 2024
View: 1438   Download: 45
Correspondence to editorial on “Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients”
Xiaoqian Xu, Hong You, Jidong Jia, Yuanyuan Kong
Clin Mol Hepatol. 2024;30(4):994-996.   Published online July 23, 2024
View: 1538   Download: 37  Web of Science: 1  Crossref: 1
Correspondence to editorial on “Classification of microvascular invasion of hepatocellular carcinoma: correlation with prognosis and magnetic resonance imaging”
Haeryoung Kim, Dong Ho Lee, Yoon Jung Hwang
Clin Mol Hepatol. 2024;30(4):992-993.   Published online August 5, 2024
View: 1404   Download: 44  Crossref: 1
Correspondence to editorial on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis”
Hayeon Kim, Min Jeong Park, Myeong Gyu Kim, Kyungim Kim
Clin Mol Hepatol. 2024;30(4):989-991.   Published online August 27, 2024
View: 1402   Download: 50  Crossref: 1
Correspondence to editorial on “Protein-centric omics analysis reveals circulating complements linked to non-viral liver diseases as potential therapeutic targets”
Yingzhou Shi, Guandou Yuan, Xiude Fan, Chao Xu
Clin Mol Hepatol. 2024;30(4):987-988.   Published online April 19, 2024
View: 1759   Download: 47
Special Topic
A new Korean nomenclature for steatotic liver disease
Nonalcoholic Fatty Liver Disease (NAFLD) Nomenclature Revision Consensus Task Force on behalf of the Korean Association for the Study of the Liver (KASL)
Clin Mol Hepatol. 2024;30(Suppl):S214-S216.   Published online July 1, 2024
View: 1977   Download: 96  Crossref: 2
Special Issue
2011
KASL clinical practice guidelines for noninvasive tests to assess liver fibrosis in chronic liver disease
Mi Na Kim, Ji Won Han, Jihyun An, Beom Kyung Kim, Young-Joo Jin, Seung-seob Kim, Minjong Lee, Han Ah Lee, Yuri Cho, Hee Yeon Kim, Yu Rim Shin, Jung Hwan Yu, Moon Young Kim, YoungRok Choi, Young Eun Chon, Eun Ju Cho, Eun Joo Lee, Sang Gyune Kim, Won Kim, Dae Won Jun, Seung Up Kim, on behalf of The Korean Association for the Study of the Liver (KASL)
Clin Mol Hepatol. 2024;30(Suppl):S5-S105.   Published online August 19, 2024
View: 3836   Download: 247  Web of Science: 11  Crossref: 14
Reply to Correspondence
Correspondence on Letter regarding “Both liver parenchymal and non-parenchymal cells express JCAD proteins under various circumstances”
Byoung Kuk Jang
Clin Mol Hepatol. 2024;30(2):297-298.   Published online April 1, 2024
View: 2579   Download: 46
Correspondence
Harnessing hepatitis B core-related antigen measurement to optimize posttreatment monitoring
Ying-Nan Tsai, Jia-Ling Wu, Yao-Chun Hsu
Clin Mol Hepatol. 2024;30(2):293-296.   Published online February 19, 2024
View: 2348   Download: 68

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X

Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail: cmh_journal@ijpnc.com
Copyright © The Korean Association for the Study of the Liver.         
COUNTER
TODAY : 3014
TOTAL : 2790705
Close layer